Zealand Pharma Logo

Phase 2 results for Zealand Pharma’s petrelintide show meaningful weight loss with strong tolerability, highlighting treatment persistence as a key factor in obesity care.

jcst2d.com/index.php/ne...

#Petrelintide #ObesityCare #ClinicalTrials #MetabolicHealth

Zealand hit as Roche-partnered obesity drug disappoints Shares in Zealand lost a third of their value today, after the biotech reported phase 2 data with Roche-partnered weight-loss therapy petrelintide.

#Shares in #ZealandPharma lost around a third of their value today, after it reported phase 2 data with #Roche-partnered #weightloss therapy #petrelintide.

A headline for results with #petrelintide says it delivered weight loss "over 100%." Perhaps this is sufficiently absurd to make us think beyond weight loss for progress in obesity care.
#ObesityCareWeek #ZealandPharma #Roche
conscienhealth.org/2026/03/06/o...

Could amylin outshine GLP-1 in obesity? Incretin-based therapies have dominated the weight-loss Olympics, with companies chasing higher percentage losses like athletes chasing record-breaking sco...

With the #Roche and #Zealand deal for up to $5.3B for #amylin agonist #petrelintide in #obesity, re-upping my story from last week on the promise of amylin in #obesity: www.biocentury.com/article/655255

ZUPREME-1 is testing petrelintide, a weekly injection, for safe and effective weight management. A game-changer in the making!
#ObesityTreatment #WeightManagement #HealthBreakthrough #ZUPREME1 #Petrelintide #HealthNews #ClinicalTrials #ScienceMatters #MedicalInnovation #BreakingNews #HealthyLiving